Medical Oncology

General Rheumatology   

Questions discussed in this category



Are there any instances where you would prefer a biosimilar rather than the reference product? 

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?


Papers discussed in this category


JAMA network open, 2018-11-02

J Rheumatol, 2019 Apr 01

RMD Open,

Annals of internal medicine, 2018-01-16

J Immunother Cancer,

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

PET Clin, 2020 Feb 11

Rheumatology (Oxford), 2022 Jul 22

Arthritis Care Res (Hoboken), 2017 Dec

JAMA, 1999 Dec 08

Reumatologia, 2020 Feb 28